Sartorius lays out mid-term profit and growth milestones amid biopharma momentum
Sartorius AG and its listed subsidiary, Sartorius Stedim Biotech, published formal mid-term targets that commit both companies to sustained organic revenue growth and annual underlying EBITDA margin expansion beginning in 2027. The guidance reflects expectations of continued biopharma-led demand, divergent division-level pacing, and caution around …